Is Virpax Pharmaceuticals, Inc. (VRPX) a Buy, Sell, or Hold?
OTC : VRPX
Virpax Pharmaceuticals, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 51
- Average Volume
- 410
- Market Capitalization
- $124
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $0.10
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.63
Company Overview
OTC
Jatinder Dhaliwal
Biotechnology
Healthcare
VRPX
2
US
USD
Liquidity Metrics
0.00
0.63
0.63
0.61
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-3928.38
Profitability
-$70.91
-$12.07M
0.00%
0.00%
-2364.82%
-775.72%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
$3.00
$3.00
$3.00
0/5
1 Analysts
-100.00%
Financial Health Scores
-90.79
0/9
-$913.76K
$1.56M
$2.47M
-$12.08M
Key Metrics (TTM)
-$1.51M
0.00
0.13
0.63
-2364.82%
1322.00%
-2836408.54%
-13478145161.29%
0 days
Company Executives
| Name | Title |
|---|---|
| Jatinder Dhaliwal | Interim Chief Financial Officer, Chief Executive Officer & Director |
| Sheila A. Mathias | Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About Virpax Pharmaceuticals, Inc. (OTC:VRPX) Stock
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineer ... ed to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
Frequently Asked Questions
-
What is the current Virpax Pharmaceuticals, Inc. (VRPX) stock price?
-
Virpax Pharmaceuticals, Inc.(OTC:VRPX) stock price is $0.0001 in the last trading session. During the trading session, VRPX stock reached the peak price of $0.1 while $0.0001 was the lowest point it dropped to. The percentage change in VRPX stock occurred in the recent session was 0.0% while the dollar amount for the price change in VRPX stock was $0.
-
VRPX's industry and sector of operation?
-
The OTC listed VRPX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VRPX?
-
Jatinder Dhaliwal | Interim Chief Financial Officer, Chief Executive Officer & Director
Sheila A. Mathias | Chief Scientific Officer
|
|
| -
How many employees does VRPX have?
-
Number of VRPX employees currently stands at 2. VRPX operates from 1055 Westlakes Drive, Berwyn, PA 19312, US.
-
Link for VRPX official website?
-
Official Website of VRPX is: https://www.virpaxpharma.com
-
How do I contact VRPX?
-
VRPX could be contacted at phone #610 727 4597 and can also be accessed through its website. VRPX operates from 1055 Westlakes Drive, Berwyn, PA 19312, US.
-
How many shares of VRPX are traded daily?
-
The average number of VRPX shares traded daily for last 3 months was 410.
-
What is the market cap of VRPX currently?
-
The market value of VRPX currently stands at $124 with its latest stock price at $0.0001